News & Updates
Filter by Specialty:
Subjective cognitive decline a red flag for Alzheimer’s disease
Subjective cognitive decline appears to be indicative of stage 2 Alzheimer’s disease, where individuals exhibit mild changes in mood or behaviour and subtle objective cognitive decline although not to the point of meeting mild cognitive impairment criteria, as suggested in a study.
Subjective cognitive decline a red flag for Alzheimer’s disease
22 May 2022
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
No apparent link between COVID-19 vax and cerebrovascular outcomes
13 May 2022
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.